Page 4 - Mitchell Steiner News Today

The biotech's experimental oral COVID-19 treatment could be a game changer.

12.05.2022 - -FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Application Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients- -IDMC Unanimously Votes to ...

Call End: Veru Inc. (NASDAQ:NASDAQ:VERU) Q2 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Samuel Fisch - Executive Director, Investor Relations and Corporate...

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest...

New drug ‘slashed’ deaths among patients with severe COVID, maker claims

Veru has reported interim analysis data from a Phase III trial, where sabizabulin lowered mortality by 55% in hospitalised Covid-19 patients.

Stock futures edge lower, Treasury yields rise ahead of march CPI data; White House braced for extraordinarily elevated March inflation reading; Veru shares surge after impressive Covid treatment data; Cisco shares slide on Morgan Stanley, Citigroup downgrades and Starbucks shares slip after Citigroup downgrade

A late-stage trial was halted after strong early results, according to the company, but the data have not yet been published or peer-reviewed.

Veru (VERU) stock is taking off on Monday as investors react to recent clinical trial news about the company's Covid-19 treatment.

The biotech's experimental COVID-19 treatment could be a game changer.